A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo)pericarditis: incidence, risk factors, clinical characteristics and outcomes.
Òscar MiròManel SabatéSònia JiménezAlexandre MebazaaGemma Martínez-NadalPascual PiñeraGuillermo Burillo-PutzeAlfonso MartínFrancisco Javier Martín-SánchezJavier JacobAitor Alquézar-ArbéEric Jorge García-LamberechtsPere LlorensJuan González Del Castillonull nullnull nullPublished in: Emergency medicine journal : EMJ (2022)
AMP is unusual as a form of COVID-19 presentation (about 1‰ cases), but SI is more than fourfold higher than non-COVID population, and it is less symptomatic, more severe and has higher in-hospital mortality; therefore, rapid recognition, echocardiographic assessment of myopericardial inflammation/dysfunction and treatment with vasoactive drugs when needed are recommended in AMP in patients with COVID-19.
Keyphrases
- risk factors
- coronavirus disease
- sars cov
- case control
- protein kinase
- oxidative stress
- drug induced
- liver failure
- pulmonary hypertension
- respiratory failure
- respiratory syndrome coronavirus
- mitral valve
- early onset
- left atrial
- room temperature
- heart failure
- extracorporeal membrane oxygenation
- hepatitis b virus
- weight loss
- quantum dots
- acute respiratory distress syndrome
- mechanical ventilation